Lung cancer is a fatal and the most common malignancy globally. Despite the significant therapeutic benefits of immune checkpoint inhibitors (ICIs), 60%-80% of patients respond poorly to immunotherapy. The identification of reliable predictive biomarkers is es... ...

请注册登录后继续浏览